Background
same time, available variant calling software for targeted deep sequencing experiments have been typically developed for and tested on Illumina data [9] .
Compared to Illumina, Ion Torrent sequencing has a higher per base error rate and an associated lower accuracy in identifying mutations [10, 11] . However, it has the advantage of requiring lower amounts of input DNA and it offers both reduced cost and turnaround time.
Thus, it is a cost-effective strategy for screening large cohorts of patients and it is particularly suited for point-of-care clinical applications [1] , for example in conjunction with the Ion AmpliSeq Cancer Hotspot Panel. Given its translational potential, there is a real need to improve the variant calling workflow and recently a number of methods have been developed to deal specifically with Ion Torrent data [12, 13, 14] .
Here we introduce AmpliSolve, a new bioinformatics method to detect SNVs in targeted deep sequencing data. It combines in-silico background error estimation with statistical modeling and it is particularly suited to deal with data of comparatively high noise levels, similar to the ones produced by the Ion AmpliSeq library preparation. In order to estimate background noise levels per position, strand and nucleotide substitution, AmpliSolve takes as input deepsequencing data from a set of normal samples. This information is then fed to a Poisson model for the identification of SNVs. Experimental results using normal samples (selfconsistency test), synthetic variants and clinical data sequenced with a custom Ion AmpliSeq gene panel, demonstrate that AmpliSolve achieves a good trade-off between precision and sensitivity, even for VAF values below 5% (and as low as 1%).
Methods

Method overview
AmpliSolve consists of two main programs written in C++: AmpliSolveErrorEstimation and AmpliSolveVariantCalling. AmpliSolveErrorEstimation requires the availability of a set of normal samples processed with the deep sequencing platform and panel of choice. Here, we focus on the Ion Torrent Personal Genome Machine (PGM) and a custom AmpliSeq panel, a technology known to have relatively high rates of sequencing error compared to others. The program uses the normal samples to infer position-specific, nucleotide specific and strandspecific background sequencing error levels (noise) across the targeted regions. Execution of AmpliSolveErrorEstimation is performed only once per panel design. Error estimates are then used as input to the AmpliSolveVariantCalling program for SNVs' detection. The procedures for in-silico noise estimation and SNV identification are described below. In Figure 1 we present a graphical overview of the AmpliSolve computational workflow.
In-silico identification of the background sequencing error
Our strategy for estimating background error levels, implemented in the AmpliSolveErrorEstimation program, is based on the assumption that alternative alleles observed at VAF<5% in normal samples are, in the majority of cases, the result of sequencing errors (see Figure S1 for the distribution of non-reference allele frequencies in normal samples showing the separation between heterozygous germline variant and lower frequency 'noise' variants). Accordingly, we utilize a set of normal samples to estimate background noise in our custom panel. Notably, we estimate error levels separately for each genomic position, each nucleotide (alternative allele) and each of the two (forward and reverse) strands. Thus, for each genomic position we generate six error estimates (i.e. two each for the three alternative alleles). Error estimates are fed to a Poisson model, which is then used to calculate the p-value of the observed substitutions representing true variants versus them being noise. The detailed implementation is as follows. We first extract "raw" counts for each position, alternative allele and strand from the BAM files [15] of a set of N normal samples using the ASEQ software [16] . We run ASEQ with the quality parameters suggested by the authors of a previous study based on Ion AmpliSeq data [17] , namely: minimum base quality = 20, minimum read quality = 20 and minimum read coverage = 20. At every genomic position, we estimate the background error s separately for each alternative allele α and strand (+ or -) by calculating the fraction of reads carrying the alternative allele on a given strand across all normal samples. More specifically we use the following formula:
and
We denote with R i α,+ and R i α,-the number of reads supporting the alternative allele α on the forward and reverse strand, respectively, in normal sample i. We denote with RD i + and RD i -the total number of reads (read depth) at the genomic position of interest on the forward and reverse strand, respectively, in normal sample i. Summations are taken over all normal samples utilized for the error estimation. C in equation (1) is a constant pseudo-count parameter that is introduced to mitigate the problem of positions in which the alternative allele read count might be underestimated (e.g. due to a relatively low read depth at a given position in the normal samples). Note that if at a given genomic position a normal sample has an alternative allele with VAF > 5%, we do not consider it for the summations in (1a) and (1b) for that position. In fact, a frequency of >5% is more likely to represent either a real variant (i.e. a single nucleotide polymorphism) or a particularly 'noisy' position in the sample and thus we opt to leave it out of the error estimation. For a given position, we additionally discard normal samples that have <100 reads on the forward or on the reverse strand (low coverage). Positions for which 2/3 or more of the normal samples are excluded from the error estimation are considered non-callable. Note that non-callable positions may include cases in which an alternative allele is frequent in the general population or over-represented in the specific set of normal samples used for the error estimation. However, given that AmpliSolve main goal is the identification of somatic mutations this does not constitute a major limitation.
SNV detection using a cumulative Poisson distribution
For every alternative allele substitution on a given + or -strand with non-zero variant read count k +/-in a sample of interest, the AmpliSolveVariantCalling program uses a Poisson model to calculate the probability that k +/-or more variant reads are produced by sequencing errors, i.e. the p-value. At any given position, the calculated p-value is a function of the normal sample-based sequencing error s +/-from previous section and of both the number of reads k +/-supporting the alternative allele on a given strand and of the read depth K +/-for the same strand in the sample of interest. In particular:
Where, for better readability, on the right side of the equation we have omitted all +/-symbols for k, K and s. We observe that K*s is the expected number of random substitutions for a e) 'HomoPolymerRegion' if the SNV is located within a homopolymer region using the same criteria as in [18] .
f) 'PositionWithHighNoise' if the SNV is supported by more than 5 reads per strand but the associated VAF is lower than the maximum VAF at this position across all normal samples in the training set.
If no warning is issued, AmpliSolve assigns a 'PASS' quality flag to the SNV.
Performance measures
To assess AmpliSolve's success in detecting SNVs, we use a number of performance metrics: 
Clinical data used in this study
For the development and evaluation of AmpliSolve, we have access to an extensive collection of clinical samples from castration-resistant prostate cancer (CRPC) patients, part of which had been already presented in previous publications [17, 19, 20, 21] the sequencing protocol, data processing and additional information about the application of our custom Ion AmpliSeq panel in CRPC diagnostic studies can be found in [17] and [19] .
These papers also include a description of a variant caller that we used as starting point for developing AmpliSolve. We call variants in these Ion AmpliSeq data with our program (p.T878A). ddPCR in the plasma samples was performed using 2-4 ng of DNA, using Life
Technologies Custom Taqman snp genotyping assay (AH0JFRC), C_175239649_10 and C_175239651_10, respectively. Following droplet generation (AutoDg, Bio-Rad) and PCR, samples were run on the Bio-Rad QX200 droplet reader and analyzed using the QuantaSoft software.
WGS variant calling pipeline
Illumina Whole Genome Sequencing (WGS) data have been processed using standard tools, such as Skewer [23] for adapter trimming, BWA-MEM [24] for mapping and Picard [25] for duplicate removal. In order to call SNVs we run a previously developed pipeline [22] that utilizes jointly Mutect [26] and Platypus [18] (throughout the manuscript this pipeline is denoted as MutPlat). Briefly, we first run Mutect (default parameters) on each paired tumournormal samples. Then, we use Mutect's calls as priors for Platypus and jointly call variants on all tumors and matched normal samples of a patient.
Germline variants are identified as those variants called in the normal (GT=0/1 or 1/1) with a PASS filter. Additionally, we accept a variant with any flag (e.g. 'badReads') if present in 1000 genomes. For AmpliSolve validation purposes we consider only tumor samples but include both germline and somatic SNVs. By including germline SNVs, in particular, we are able to test a higher number of low VAF mutations than would be possible when considering only somatic mutations. Indeed, while somatic deletions cause loss of some germline SNPs in tumour DNA, germline DNA contamination (i.e. <100% tumor purity) means that these mutations are still present in the tumor samples, albeit at lower VAF. In some cases, depending on tumor purity and depth of sequencing coverage, the detected VAF can even be nominally zero in the tumor.
To call a somatic SNV we require all of the following criteria to be met: i) Platypus filter: [16] . Once the read count files have been produced, the user needs to set the value of the C pseudo-count parameter (equation (1)). The choice of C will depend on the trade-off between precision and sensitivity the user is interested in. Users can refer to the benchmarking experiments performed in this paper. In general, values of C between 0.001 and 0.01 should suit most applications.
Once the error matrix has been calculated, it can be fed to the AmpliSolveVariantCalling program together with read count files for the tumour samples again to be produced by running ASEQ. Note that AmpliSolveVariantCalling does not require matched normaltumour samples for calling SNVs. In fact, AmpliSolveVariantCalling calls all variants it can find in the tumour sample, including germline variants. To separate germline from somatic variants users will need to run AmpliSolveVariantCalling on a matched normal sample and take the difference between the two output files. Command-line syntax for running AmpliSolveErrorEstimation and AmpliSolveVariantCalling is provided on github.
Results and Discussion
Sequencing error estimation, self-consistency test and AmpliSolve FDR
AmpliSolve estimates the background sequencing noise by analyzing the distribution of alternative allele in normal samples. As previously reported, PGM errors tend to be systematic [11] and AmpliSolve assigns a separate error level to each genomic position, each alternative allele and each strand (see Figure S2 ). These are then utilized to build the Poisson models that are at the core of AmpliSolve SNV calling (Methods). In this section, we study AmpliSolve variant calling performance as a function of two parameters: the pseudo-count C (equation (1) in Methods), and the number of normal samples N that are used to calculate the error estimations. C is the only user-adjustable parameter of our method. The number of samples N, instead, depends on sample availability for a given panel.
We perform a self-consistency test using sets of normal samples to train our models and other, non-overlapping normal samples for testing them. Figure S1 ). Thus, in order to truly test AmpliSolve Sensitivity, we have to perform a different kind of experiment, which we describe in the next section.
Synthetic variants test for TPR estimation
In order to test the sensitivity of our method at low VAFs (0.5% to 4%), we design the following experiment. We first select two amplicons spanning the AR gene (1,017 genomic positions overall); the AR gene is chosen because clinically relevant but for this purpose other choices would be equally valid. Then, we use 120 normal samples randomly selected from the full set of 184 described in Methods to estimate the errors at each position in the two amplicons, for each nucleotide and each strand, according to formula (1) . Next, we test the method's sensitivity on synthetic variants. For each possible alternative allele at each of the 1,017 amplicon positions, we set read depth to a fixed value COV and the number of reads supporting the allele to a value 2a (a supporting reads on the forward strand and a on the reverse strand). We use COV=800, 1600, 3200, 6400 (values in this range apply to more than 60% of full panel positions with coverage >200, see Figure S3 ) and for each value of COV we select a corresponding to VAFs of 0.5%, 1%, 1.25%, 2%, 3% and 4%. For example for COV=800 we test a=2, 4, 5, 8, 12, 16 . We then apply the Poisson models previously trained on the 120 normal samples to predict variants at each position and for each alternative allele and consider only AmpliSolve calls with a 'PASS' quality flag (Methods). We consider all synthetic variants to be positives (thus, no FDR can be calculated in this case) and ask how many of these can be detected by AmpliSolve. We stress that while in each experiment the VAF is by design the same at all positions and for each alternative allele and strand, following estimation from the normal samples the error estimate is position-, alternative allele-and strand-dependent. We calculate the TPR for all combinations of COV and VAF. 
Conclusions
In this study, we present AmpliSolve, a new bioinformatics method that combines positionspecific, nucleotide-specific and strand-specific background error estimation with statistical modeling for SNV detection in amplicon-based deep sequencing data. AmpliSolve is originally designed for the Ion AmpliSeq platform that is affected by higher error levels compared to, for example, Illumina platforms. Our method is based on the estimation of noise levels from normal samples and uses a Poisson model to calculate the p-value of the detected variant. We assess AmpliSolve's performance with experiments that use normal samples Written informed consent was obtained from all patients.
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